Changes in Hong Kong stocks | BeiGene (06160) rose more than 4% to invest additional US$300 million to expand US production layout

The Zhitong Finance App learned that BeiGene (06160) rose more than 4%. As of press release, it had risen 4.02% to HK$202.6, with a turnover of HK$170 million.

According to the news, on July 23, BeiGene announced that it will invest an additional 300 million US dollars to expand its flagship production base and clinical research and development center located in the Princeton Western Innovation Park in Hopewell, New Jersey, USA, and increase production capacity for small molecule drugs. This additional production capacity will support the company's multiple hematologic oncology projects, as well as pipeline projects for breast cancer, gynecologic tumors, lung cancer, liver cancer, gastrointestinal tumors, and other tumors.

Huafu Securities recently pointed out that BeiGene has become a lightweight MNC with stable hematopoietic capacity, global commercial execution, and systematic R&D efficiency. Its industry-leading clinical operation and R&D model is an invisible moat that is undervalued in addition to pipeline value. The combined development of the BeiGene pipeline makes the product value greater than the product's valuation simply summed up.